RCS - Scancell Hlds - Scancell Attendance at Upcoming Conferences

Scancell HoldingsAnnouncement

12/03/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240312:nRSL4269Ga&default-theme=true

RNS Number : 4269G  Scancell Holdings Plc  12 March 2024

12 March 2024

 

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell Announces its Attendance at Upcoming Conferences

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer and infectious disease, is pleased to confirm that it
will be presenting at, and will also attend, several upcoming conferences and
events. Presentations at these high-profile conferences follow the significant
recent progress that Scancell has made in both pre-clinical and clinical
development.

 

These include:

 

·      14th World ADC (https://worldadc-europe.com/) taking place in
London, UK from 12-15 March.

Mandeep Sehmi, Head of Business Development, will be presenting at the
conference.

Title: Glymab ADC for targeting cancers with high unmet need

Date and Time: Wednesday 13(th) March 5pm GMT

 

·      Oxford Global - Biologics 2024
(https://oxfordglobal.com/biologics/events/biologics-2024) taking place in
London, UK from 13-15 March

Poonam Vagehla and Foram Dave, Scientists at Scancell, will be presenting at
the conference.

Session Title: Nextgen Multispecifics, Cell Engagers & Other New
Modalities

Title: Glycan Targeting Antibodies for T Cell Redirection

Date and Time: Friday 15(th) March at 3:10 pm GMT

 

·      BIO-Europe Spring (https://informaconnect.com/bioeurope-spring/)
in Barcelona, Spain from 18-20 March

Mandeep Sehmi, Head of Business Development and Mireille Vankemmelbeke, PI at
Scancell will be attending the conference.

 

·      21st CIMT Annual Meeting (https://www.meeting.cimt.eu/) taking
place in Mainz, Germany from 15-17 May

Samantha Paston, Head of Translational Research, will be attending the
conference.

 

If you would like to arrange a meeting with management, please contact
commercial.enquiries@scancell.co.uk
(mailto:commercial.enquiries@scancell.co.uk) .

 

-ENDS-

 

 For further information, please contact:
 Scancell Holdings plc                                                +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)  +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)
 Nick Adams/Nick Harland (Corporate Broking)

 WG Partners LLP (Joint Broker)                                       +44 (0) 20 3705 9330
 David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

 Panmure Gordon (UK) Limited (Joint Broker)                           +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 

 ICR Consilium                               +44 (0) 20 3709 5700
 Mary-Jane Elliott/Matthew Neal/Chris Welsh  scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer and infectious disease. The Company is building a pipeline of
innovative products by utilising its four technology platforms: Moditope(®)
and ImmunoBody(®) for vaccines and GlyMab(®) and AvidiMab(®) for
antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADBGDXSUBDGSB